Ilkun Olesya, Kazory Amir
Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, FL 32610, United States.
World J Cardiol. 2025 Jul 26;17(7):107539. doi: 10.4330/wjc.v17.i7.107539.
Over the last decade, neprilysin inhibition has been established as the cornerstone of therapy in heart failure (HF). Patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) have a high prevalence of HF; the concomitant presence of HF and CKD or ESKD, conventionally termed chronic cardiorenal syndrome, is associated with a higher rate of adverse outcomes, including increased hospitalizations and mortality. The use of this novel class of medications in patients with advanced CKD or ESKD has been limited due to uncertainty about their efficacy and safety. Herein, we provide an overview of the available evidence on the use of neprilysin inhibition in HF and discuss how those concepts would apply to patients with concomitant CKD or ESKD.
在过去十年中，抑制中性肽链内切酶已成为心力衰竭（HF）治疗的基石。慢性肾脏病（CKD）和终末期肾病（ESKD）患者中HF的患病率很高；HF与CKD或ESKD同时存在，传统上称为慢性心肾综合征，与更高的不良结局发生率相关，包括住院率和死亡率增加。由于这类新型药物在晚期CKD或ESKD患者中的疗效和安全性尚不确定，其应用受到限制。在此，我们概述了关于抑制中性肽链内切酶在HF治疗中应用的现有证据，并讨论这些概念如何适用于合并CKD或ESKD的患者。
